Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Plus News From Resverlogix, Sun And Syntekabio

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

New_Delhi_Train
New Delhi: Trains and other aspects of life in India have resumed after more than two months of lockdown, despite COVID-19 cases continuing to surge in the country.

Eli Lilly & Co. has begun Phase I trials of anti-COVID-19 antibody candidate which could be used both as a treatment and a means of preventing infection.

The candidate LY-CoV555, is the lead antibody from Lilly's collaboration with Vancouver-based AbCellera, which has discovered and selected its lead...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip